CC50A Rabbit Polyclonal Antibody
To Order : [email protected]
CC50A Polyclonal Antibody |
E44H09165 |
EnoGene |
100ul |
EUR 255 |
Description: Biotin-Conjugated, FITC-Conjugated , AF350 Conjugated , AF405M-Conjugated ,AF488-Conjugated, AF514-Conjugated ,AF532-Conjugated, AF555-Conjugated ,AF568-Conjugated , HRP-Conjugated, AF405S-Conjugated, AF405L-Conjugated , AF546-Conjugated, AF594-Conjugated , AF610-Conjugated, AF635-Conjugated , AF647-Conjugated , AF680-Conjugated , AF700-Conjugated , AF750-Conjugated , AF790-Conjugated , APC-Conjugated , PE-Conjugated , Cy3-Conjugated , Cy5-Conjugated , Cy5.5-Conjugated , Cy7-Conjugated Antibody |
CC50A Polyclonal Antibody |
E11-201558 |
EnoGene |
100ug/100ul |
EUR 225 |
Description: Available in various conjugation types. |
CC50A Polyclonal Antibody |
MBS8530912-01mg |
MyBiosource |
0.1mg |
EUR 305 |
CC50A Polyclonal Antibody |
MBS8530912-01mLAF405L |
MyBiosource |
0.1mL(AF405L) |
EUR 465 |
CC50A Polyclonal Antibody |
MBS8530912-01mLAF405S |
MyBiosource |
0.1mL(AF405S) |
EUR 465 |
CC50A Polyclonal Antibody |
MBS8530912-01mLAF610 |
MyBiosource |
0.1mL(AF610) |
EUR 465 |
CC50A Polyclonal Antibody |
MBS8530912-01mLAF635 |
MyBiosource |
0.1mL(AF635) |
EUR 465 |
CC50A Polyclonal Antibody |
UB-GEN-6291 |
UpingBio |
100 ul |
EUR 200 |
CC74A Rabbit Polyclonal Antibody |
JOT-AP07265-100ul |
Jotbody |
100ul |
EUR 220 |
CC74A Rabbit Polyclonal Antibody |
JOT-AP07265-50ul |
Jotbody |
50ul |
EUR 144 |
C2C4A Rabbit Polyclonal Antibody |
JOT-AP00934-100ul |
Jotbody |
100ul |
EUR 220 |
C2C4A Rabbit Polyclonal Antibody |
JOT-AP00934-50ul |
Jotbody |
50ul |
EUR 144 |
C163A Rabbit Polyclonal Antibody |
BT-AP00915-100ul |
Jiaxing Korain Biotech Ltd (BT Labs) |
100ul |
Ask for price |
|
Description: It is uncertain whether Met-1 or Met-6 is the initiator.|disease:The soluble form (sCD163) in plasma is a novel parameter in diseases affecting macrophage function and monocyte/macrophage load in the body. The concentration of sCD163 is probably reflecting the number of macrophages of the 'alternative macrophage activation' phenotype with a high CD163 expression playing a major role in dampening the inflammatory response and scavenging components of damaged cells. This has initiated a number of clinical studies for evaluation of sCD163 as a disease marker in inflammatory conditions e.g. infection| autoimmune disease| transplantation| atherosclerosis and cancer.|The SRCR domain 3 mediates calcium-sensitive interaction with hemoglobin/haptoglobin complexes.|Acute phase-regulated receptor involved in clearance and endocytosis of hemoglobin/haptoglobin complexes by macrophages and may thereby protect tissues from free hemoglobin-mediated oxidative damage. May play a role in the uptake and recycling of iron| via endocytosis of hemoglobin/haptoglobin and subsequent breakdown of heme. Binds hemoglobin/haptoglobin complexes in a calcium-dependent and pH-dependent manner. Exhibits a higher affinity for complexes of hemoglobin and multimeric haptoglobin of HP*1F phenotype than for complexes of hemoglobin and dimeric haptoglobin of HP*1S phenotype. Induces a cascade of intracellular signals that involves tyrosine kinase-dependent calcium mobilization| inositol triphosphate production and secretion of IL6 and CSF1. Isoform 3 exhibits the higher capacity for ligand endocytosis and the more pronounced surface expression when expressed in cells.|After shedding| the soluble form (sCD163) may play an anti-inflammatory role| and may be a valuable diagnostic parameter for monitoring macrophage activation in inflammatory conditions.|induction:Induced by anti-inflammatory mediators such as glucocorticoids| IL6 and IL10; suppressed by proinflammatory mediators like lipopolysaccharide (LPS)| Interferon gamma/IFNG| and tumor necrosis factor alpha.|miscellaneous:Intravenous lipopolysaccharide (LPS) produces a rapid rise of sCD163 in plasma of patient as it induces metalloproteinase-mediated shedding from monocytes surface. Long-term LPS infusion finally increases expression of the membrane-bound form on circulating monocytes.|PTM:A soluble form (sCD163) is produced by proteolytic shedding which can be induced by lipopolysaccharide| phorbol ester and Fc region of immunoglobulin gamma. This cleavage is dependent on protein kinase C and tyrosine kinases and can be blocked by protease inhibitors. The shedding is inhibited by the tissue inhibitor of metalloproteinase TIMP3| and thus probably induced by membrane-bound metalloproteinases ADAMs.|PTM:Phosphorylated.|Contains 9 SRCR domains.|subcellular location:Isoform 1 and isoform 2 show a lower surface expression when expressed in cells.|subunit:Interacts with CSNK2B.|tissue specificity:Expressed in monocytes and mature macrophages such as Kupffer cells in the liver| red pulp macrophages in the spleen| cortical macrophages in the thymus| resident bone marrow macrophages and meningeal macrophages of the central nervous system. Expressed also in blood. Isoform 1 is the lowest abundant in the blood. Isoform 2 is the lowest abundant in the liver and the spleen. Isoform 3 is the predominant isoform detected in the blood.| |
C163A Rabbit Polyclonal Antibody |
BT-AP00915-20ul |
Jiaxing Korain Biotech Ltd (BT Labs) |
20ul |
Ask for price |
|
Description: It is uncertain whether Met-1 or Met-6 is the initiator.|disease:The soluble form (sCD163) in plasma is a novel parameter in diseases affecting macrophage function and monocyte/macrophage load in the body. The concentration of sCD163 is probably reflecting the number of macrophages of the 'alternative macrophage activation' phenotype with a high CD163 expression playing a major role in dampening the inflammatory response and scavenging components of damaged cells. This has initiated a number of clinical studies for evaluation of sCD163 as a disease marker in inflammatory conditions e.g. infection| autoimmune disease| transplantation| atherosclerosis and cancer.|The SRCR domain 3 mediates calcium-sensitive interaction with hemoglobin/haptoglobin complexes.|Acute phase-regulated receptor involved in clearance and endocytosis of hemoglobin/haptoglobin complexes by macrophages and may thereby protect tissues from free hemoglobin-mediated oxidative damage. May play a role in the uptake and recycling of iron| via endocytosis of hemoglobin/haptoglobin and subsequent breakdown of heme. Binds hemoglobin/haptoglobin complexes in a calcium-dependent and pH-dependent manner. Exhibits a higher affinity for complexes of hemoglobin and multimeric haptoglobin of HP*1F phenotype than for complexes of hemoglobin and dimeric haptoglobin of HP*1S phenotype. Induces a cascade of intracellular signals that involves tyrosine kinase-dependent calcium mobilization| inositol triphosphate production and secretion of IL6 and CSF1. Isoform 3 exhibits the higher capacity for ligand endocytosis and the more pronounced surface expression when expressed in cells.|After shedding| the soluble form (sCD163) may play an anti-inflammatory role| and may be a valuable diagnostic parameter for monitoring macrophage activation in inflammatory conditions.|induction:Induced by anti-inflammatory mediators such as glucocorticoids| IL6 and IL10; suppressed by proinflammatory mediators like lipopolysaccharide (LPS)| Interferon gamma/IFNG| and tumor necrosis factor alpha.|miscellaneous:Intravenous lipopolysaccharide (LPS) produces a rapid rise of sCD163 in plasma of patient as it induces metalloproteinase-mediated shedding from monocytes surface. Long-term LPS infusion finally increases expression of the membrane-bound form on circulating monocytes.|PTM:A soluble form (sCD163) is produced by proteolytic shedding which can be induced by lipopolysaccharide| phorbol ester and Fc region of immunoglobulin gamma. This cleavage is dependent on protein kinase C and tyrosine kinases and can be blocked by protease inhibitors. The shedding is inhibited by the tissue inhibitor of metalloproteinase TIMP3| and thus probably induced by membrane-bound metalloproteinases ADAMs.|PTM:Phosphorylated.|Contains 9 SRCR domains.|subcellular location:Isoform 1 and isoform 2 show a lower surface expression when expressed in cells.|subunit:Interacts with CSNK2B.|tissue specificity:Expressed in monocytes and mature macrophages such as Kupffer cells in the liver| red pulp macrophages in the spleen| cortical macrophages in the thymus| resident bone marrow macrophages and meningeal macrophages of the central nervous system. Expressed also in blood. Isoform 1 is the lowest abundant in the blood. Isoform 2 is the lowest abundant in the liver and the spleen. Isoform 3 is the predominant isoform detected in the blood.| |
C163A Rabbit Polyclonal Antibody |
BT-AP00915-50ul |
Jiaxing Korain Biotech Ltd (BT Labs) |
50ul |
Ask for price |
|
Description: It is uncertain whether Met-1 or Met-6 is the initiator.|disease:The soluble form (sCD163) in plasma is a novel parameter in diseases affecting macrophage function and monocyte/macrophage load in the body. The concentration of sCD163 is probably reflecting the number of macrophages of the 'alternative macrophage activation' phenotype with a high CD163 expression playing a major role in dampening the inflammatory response and scavenging components of damaged cells. This has initiated a number of clinical studies for evaluation of sCD163 as a disease marker in inflammatory conditions e.g. infection| autoimmune disease| transplantation| atherosclerosis and cancer.|The SRCR domain 3 mediates calcium-sensitive interaction with hemoglobin/haptoglobin complexes.|Acute phase-regulated receptor involved in clearance and endocytosis of hemoglobin/haptoglobin complexes by macrophages and may thereby protect tissues from free hemoglobin-mediated oxidative damage. May play a role in the uptake and recycling of iron| via endocytosis of hemoglobin/haptoglobin and subsequent breakdown of heme. Binds hemoglobin/haptoglobin complexes in a calcium-dependent and pH-dependent manner. Exhibits a higher affinity for complexes of hemoglobin and multimeric haptoglobin of HP*1F phenotype than for complexes of hemoglobin and dimeric haptoglobin of HP*1S phenotype. Induces a cascade of intracellular signals that involves tyrosine kinase-dependent calcium mobilization| inositol triphosphate production and secretion of IL6 and CSF1. Isoform 3 exhibits the higher capacity for ligand endocytosis and the more pronounced surface expression when expressed in cells.|After shedding| the soluble form (sCD163) may play an anti-inflammatory role| and may be a valuable diagnostic parameter for monitoring macrophage activation in inflammatory conditions.|induction:Induced by anti-inflammatory mediators such as glucocorticoids| IL6 and IL10; suppressed by proinflammatory mediators like lipopolysaccharide (LPS)| Interferon gamma/IFNG| and tumor necrosis factor alpha.|miscellaneous:Intravenous lipopolysaccharide (LPS) produces a rapid rise of sCD163 in plasma of patient as it induces metalloproteinase-mediated shedding from monocytes surface. Long-term LPS infusion finally increases expression of the membrane-bound form on circulating monocytes.|PTM:A soluble form (sCD163) is produced by proteolytic shedding which can be induced by lipopolysaccharide| phorbol ester and Fc region of immunoglobulin gamma. This cleavage is dependent on protein kinase C and tyrosine kinases and can be blocked by protease inhibitors. The shedding is inhibited by the tissue inhibitor of metalloproteinase TIMP3| and thus probably induced by membrane-bound metalloproteinases ADAMs.|PTM:Phosphorylated.|Contains 9 SRCR domains.|subcellular location:Isoform 1 and isoform 2 show a lower surface expression when expressed in cells.|subunit:Interacts with CSNK2B.|tissue specificity:Expressed in monocytes and mature macrophages such as Kupffer cells in the liver| red pulp macrophages in the spleen| cortical macrophages in the thymus| resident bone marrow macrophages and meningeal macrophages of the central nervous system. Expressed also in blood. Isoform 1 is the lowest abundant in the blood. Isoform 2 is the lowest abundant in the liver and the spleen. Isoform 3 is the predominant isoform detected in the blood.| |
C163A Rabbit Polyclonal Antibody |
BT-AP00916-100ul |
Jiaxing Korain Biotech Ltd (BT Labs) |
100ul |
Ask for price |
|
Description: It is uncertain whether Met-1 or Met-6 is the initiator.|disease:The soluble form (sCD163) in plasma is a novel parameter in diseases affecting macrophage function and monocyte/macrophage load in the body. The concentration of sCD163 is probably reflecting the number of macrophages of the 'alternative macrophage activation' phenotype with a high CD163 expression playing a major role in dampening the inflammatory response and scavenging components of damaged cells. This has initiated a number of clinical studies for evaluation of sCD163 as a disease marker in inflammatory conditions e.g. infection| autoimmune disease| transplantation| atherosclerosis and cancer.|The SRCR domain 3 mediates calcium-sensitive interaction with hemoglobin/haptoglobin complexes.|Acute phase-regulated receptor involved in clearance and endocytosis of hemoglobin/haptoglobin complexes by macrophages and may thereby protect tissues from free hemoglobin-mediated oxidative damage. May play a role in the uptake and recycling of iron| via endocytosis of hemoglobin/haptoglobin and subsequent breakdown of heme. Binds hemoglobin/haptoglobin complexes in a calcium-dependent and pH-dependent manner. Exhibits a higher affinity for complexes of hemoglobin and multimeric haptoglobin of HP*1F phenotype than for complexes of hemoglobin and dimeric haptoglobin of HP*1S phenotype. Induces a cascade of intracellular signals that involves tyrosine kinase-dependent calcium mobilization| inositol triphosphate production and secretion of IL6 and CSF1. Isoform 3 exhibits the higher capacity for ligand endocytosis and the more pronounced surface expression when expressed in cells.|After shedding| the soluble form (sCD163) may play an anti-inflammatory role| and may be a valuable diagnostic parameter for monitoring macrophage activation in inflammatory conditions.|induction:Induced by anti-inflammatory mediators such as glucocorticoids| IL6 and IL10; suppressed by proinflammatory mediators like lipopolysaccharide (LPS)| Interferon gamma/IFNG| and tumor necrosis factor alpha.|miscellaneous:Intravenous lipopolysaccharide (LPS) produces a rapid rise of sCD163 in plasma of patient as it induces metalloproteinase-mediated shedding from monocytes surface. Long-term LPS infusion finally increases expression of the membrane-bound form on circulating monocytes.|PTM:A soluble form (sCD163) is produced by proteolytic shedding which can be induced by lipopolysaccharide| phorbol ester and Fc region of immunoglobulin gamma. This cleavage is dependent on protein kinase C and tyrosine kinases and can be blocked by protease inhibitors. The shedding is inhibited by the tissue inhibitor of metalloproteinase TIMP3| and thus probably induced by membrane-bound metalloproteinases ADAMs.|PTM:Phosphorylated.|Contains 9 SRCR domains.|subcellular location:Isoform 1 and isoform 2 show a lower surface expression when expressed in cells.|subunit:Interacts with CSNK2B.|tissue specificity:Expressed in monocytes and mature macrophages such as Kupffer cells in the liver| red pulp macrophages in the spleen| cortical macrophages in the thymus| resident bone marrow macrophages and meningeal macrophages of the central nervous system. Expressed also in blood. Isoform 1 is the lowest abundant in the blood. Isoform 2 is the lowest abundant in the liver and the spleen. Isoform 3 is the predominant isoform detected in the blood.| |
C163A Rabbit Polyclonal Antibody |
BT-AP00916-20ul |
Jiaxing Korain Biotech Ltd (BT Labs) |
20ul |
Ask for price |
|
Description: It is uncertain whether Met-1 or Met-6 is the initiator.|disease:The soluble form (sCD163) in plasma is a novel parameter in diseases affecting macrophage function and monocyte/macrophage load in the body. The concentration of sCD163 is probably reflecting the number of macrophages of the 'alternative macrophage activation' phenotype with a high CD163 expression playing a major role in dampening the inflammatory response and scavenging components of damaged cells. This has initiated a number of clinical studies for evaluation of sCD163 as a disease marker in inflammatory conditions e.g. infection| autoimmune disease| transplantation| atherosclerosis and cancer.|The SRCR domain 3 mediates calcium-sensitive interaction with hemoglobin/haptoglobin complexes.|Acute phase-regulated receptor involved in clearance and endocytosis of hemoglobin/haptoglobin complexes by macrophages and may thereby protect tissues from free hemoglobin-mediated oxidative damage. May play a role in the uptake and recycling of iron| via endocytosis of hemoglobin/haptoglobin and subsequent breakdown of heme. Binds hemoglobin/haptoglobin complexes in a calcium-dependent and pH-dependent manner. Exhibits a higher affinity for complexes of hemoglobin and multimeric haptoglobin of HP*1F phenotype than for complexes of hemoglobin and dimeric haptoglobin of HP*1S phenotype. Induces a cascade of intracellular signals that involves tyrosine kinase-dependent calcium mobilization| inositol triphosphate production and secretion of IL6 and CSF1. Isoform 3 exhibits the higher capacity for ligand endocytosis and the more pronounced surface expression when expressed in cells.|After shedding| the soluble form (sCD163) may play an anti-inflammatory role| and may be a valuable diagnostic parameter for monitoring macrophage activation in inflammatory conditions.|induction:Induced by anti-inflammatory mediators such as glucocorticoids| IL6 and IL10; suppressed by proinflammatory mediators like lipopolysaccharide (LPS)| Interferon gamma/IFNG| and tumor necrosis factor alpha.|miscellaneous:Intravenous lipopolysaccharide (LPS) produces a rapid rise of sCD163 in plasma of patient as it induces metalloproteinase-mediated shedding from monocytes surface. Long-term LPS infusion finally increases expression of the membrane-bound form on circulating monocytes.|PTM:A soluble form (sCD163) is produced by proteolytic shedding which can be induced by lipopolysaccharide| phorbol ester and Fc region of immunoglobulin gamma. This cleavage is dependent on protein kinase C and tyrosine kinases and can be blocked by protease inhibitors. The shedding is inhibited by the tissue inhibitor of metalloproteinase TIMP3| and thus probably induced by membrane-bound metalloproteinases ADAMs.|PTM:Phosphorylated.|Contains 9 SRCR domains.|subcellular location:Isoform 1 and isoform 2 show a lower surface expression when expressed in cells.|subunit:Interacts with CSNK2B.|tissue specificity:Expressed in monocytes and mature macrophages such as Kupffer cells in the liver| red pulp macrophages in the spleen| cortical macrophages in the thymus| resident bone marrow macrophages and meningeal macrophages of the central nervous system. Expressed also in blood. Isoform 1 is the lowest abundant in the blood. Isoform 2 is the lowest abundant in the liver and the spleen. Isoform 3 is the predominant isoform detected in the blood.| |
C163A Rabbit Polyclonal Antibody |
BT-AP00916-50ul |
Jiaxing Korain Biotech Ltd (BT Labs) |
50ul |
Ask for price |
|
Description: It is uncertain whether Met-1 or Met-6 is the initiator.|disease:The soluble form (sCD163) in plasma is a novel parameter in diseases affecting macrophage function and monocyte/macrophage load in the body. The concentration of sCD163 is probably reflecting the number of macrophages of the 'alternative macrophage activation' phenotype with a high CD163 expression playing a major role in dampening the inflammatory response and scavenging components of damaged cells. This has initiated a number of clinical studies for evaluation of sCD163 as a disease marker in inflammatory conditions e.g. infection| autoimmune disease| transplantation| atherosclerosis and cancer.|The SRCR domain 3 mediates calcium-sensitive interaction with hemoglobin/haptoglobin complexes.|Acute phase-regulated receptor involved in clearance and endocytosis of hemoglobin/haptoglobin complexes by macrophages and may thereby protect tissues from free hemoglobin-mediated oxidative damage. May play a role in the uptake and recycling of iron| via endocytosis of hemoglobin/haptoglobin and subsequent breakdown of heme. Binds hemoglobin/haptoglobin complexes in a calcium-dependent and pH-dependent manner. Exhibits a higher affinity for complexes of hemoglobin and multimeric haptoglobin of HP*1F phenotype than for complexes of hemoglobin and dimeric haptoglobin of HP*1S phenotype. Induces a cascade of intracellular signals that involves tyrosine kinase-dependent calcium mobilization| inositol triphosphate production and secretion of IL6 and CSF1. Isoform 3 exhibits the higher capacity for ligand endocytosis and the more pronounced surface expression when expressed in cells.|After shedding| the soluble form (sCD163) may play an anti-inflammatory role| and may be a valuable diagnostic parameter for monitoring macrophage activation in inflammatory conditions.|induction:Induced by anti-inflammatory mediators such as glucocorticoids| IL6 and IL10; suppressed by proinflammatory mediators like lipopolysaccharide (LPS)| Interferon gamma/IFNG| and tumor necrosis factor alpha.|miscellaneous:Intravenous lipopolysaccharide (LPS) produces a rapid rise of sCD163 in plasma of patient as it induces metalloproteinase-mediated shedding from monocytes surface. Long-term LPS infusion finally increases expression of the membrane-bound form on circulating monocytes.|PTM:A soluble form (sCD163) is produced by proteolytic shedding which can be induced by lipopolysaccharide| phorbol ester and Fc region of immunoglobulin gamma. This cleavage is dependent on protein kinase C and tyrosine kinases and can be blocked by protease inhibitors. The shedding is inhibited by the tissue inhibitor of metalloproteinase TIMP3| and thus probably induced by membrane-bound metalloproteinases ADAMs.|PTM:Phosphorylated.|Contains 9 SRCR domains.|subcellular location:Isoform 1 and isoform 2 show a lower surface expression when expressed in cells.|subunit:Interacts with CSNK2B.|tissue specificity:Expressed in monocytes and mature macrophages such as Kupffer cells in the liver| red pulp macrophages in the spleen| cortical macrophages in the thymus| resident bone marrow macrophages and meningeal macrophages of the central nervous system. Expressed also in blood. Isoform 1 is the lowest abundant in the blood. Isoform 2 is the lowest abundant in the liver and the spleen. Isoform 3 is the predominant isoform detected in the blood.| |
C163A Rabbit Polyclonal Antibody |
JOT-AP00915-100ul |
Jotbody |
100ul |
EUR 220 |
|
C163A Rabbit Polyclonal Antibody |
JOT-AP00915-50ul |
Jotbody |
50ul |
EUR 144 |
|
C163A Rabbit Polyclonal Antibody |
JOT-AP00916-100ul |
Jotbody |
100ul |
EUR 220 |
|
C163A Rabbit Polyclonal Antibody |
JOT-AP00916-50ul |
Jotbody |
50ul |
EUR 144 |
|
C144A Rabbit Polyclonal Antibody |
JOT-AP06670-100ul |
Jotbody |
100ul |
EUR 220 |
C144A Rabbit Polyclonal Antibody |
JOT-AP06670-50ul |
Jotbody |
50ul |
EUR 144 |
CC107 Rabbit Polyclonal Antibody |
BT-AP07150-100ul |
Jiaxing Korain Biotech Ltd (BT Labs) |
100ul |
Ask for price |
|
Description: This gene encodes a membrane protein which contains a coiled-coil domain in the central region. Multiple alternatively spliced transcript variants encoding different isoforms have been found for this gene. |
CC107 Rabbit Polyclonal Antibody |
BT-AP07150-20ul |
Jiaxing Korain Biotech Ltd (BT Labs) |
20ul |
Ask for price |
|
Description: This gene encodes a membrane protein which contains a coiled-coil domain in the central region. Multiple alternatively spliced transcript variants encoding different isoforms have been found for this gene. |
CC107 Rabbit Polyclonal Antibody |
BT-AP07150-50ul |
Jiaxing Korain Biotech Ltd (BT Labs) |
50ul |
Ask for price |
|
Description: This gene encodes a membrane protein which contains a coiled-coil domain in the central region. Multiple alternatively spliced transcript variants encoding different isoforms have been found for this gene. |
CC170 Rabbit Polyclonal Antibody |
BT-AP01211-100ul |
Jiaxing Korain Biotech Ltd (BT Labs) |
100ul |
Ask for price |
|
Description: The function of this gene and its encoded protein is not known. Several genome-wide association studies have implicated the region around this gene to be involved in breast cancer and bone mineral density| but no link to this specific gene has been found. |
CC170 Rabbit Polyclonal Antibody |
BT-AP01211-20ul |
Jiaxing Korain Biotech Ltd (BT Labs) |
20ul |
Ask for price |
|
Description: The function of this gene and its encoded protein is not known. Several genome-wide association studies have implicated the region around this gene to be involved in breast cancer and bone mineral density| but no link to this specific gene has been found. |
CC170 Rabbit Polyclonal Antibody |
BT-AP01211-50ul |
Jiaxing Korain Biotech Ltd (BT Labs) |
50ul |
Ask for price |
|
Description: The function of this gene and its encoded protein is not known. Several genome-wide association studies have implicated the region around this gene to be involved in breast cancer and bone mineral density| but no link to this specific gene has been found. |
CC079 Rabbit Polyclonal Antibody |
JOT-AP07130-100ul |
Jotbody |
100ul |
EUR 220 |
CC079 Rabbit Polyclonal Antibody |
JOT-AP07130-50ul |
Jotbody |
50ul |
EUR 144 |
CC107 Rabbit Polyclonal Antibody |
JOT-AP07150-100ul |
Jotbody |
100ul |
EUR 220 |
|
CC107 Rabbit Polyclonal Antibody |
JOT-AP07150-50ul |
Jotbody |
50ul |
EUR 144 |
|
CC116 Rabbit Polyclonal Antibody |
JOT-AP07151-100ul |
Jotbody |
100ul |
EUR 220 |
CC116 Rabbit Polyclonal Antibody |
JOT-AP07151-50ul |
Jotbody |
50ul |
EUR 144 |
CC132 Rabbit Polyclonal Antibody |
JOT-AP07152-100ul |
Jotbody |
100ul |
EUR 220 |
CC132 Rabbit Polyclonal Antibody |
JOT-AP07152-50ul |
Jotbody |
50ul |
EUR 144 |
CC134 Rabbit Polyclonal Antibody |
JOT-AP07153-100ul |
Jotbody |
100ul |
EUR 220 |
CC134 Rabbit Polyclonal Antibody |
JOT-AP07153-50ul |
Jotbody |
50ul |
EUR 144 |
CC137 Rabbit Polyclonal Antibody |
JOT-AP07154-100ul |
Jotbody |
100ul |
EUR 220 |
CC137 Rabbit Polyclonal Antibody |
JOT-AP07154-50ul |
Jotbody |
50ul |
EUR 144 |
CC142 Rabbit Polyclonal Antibody |
JOT-AP07160-100ul |
Jotbody |
100ul |
EUR 220 |
CC142 Rabbit Polyclonal Antibody |
JOT-AP07160-50ul |
Jotbody |
50ul |
EUR 144 |
CC147 Rabbit Polyclonal Antibody |
JOT-AP07170-100ul |
Jotbody |
100ul |
EUR 220 |
CC147 Rabbit Polyclonal Antibody |
JOT-AP07170-50ul |
Jotbody |
50ul |
EUR 144 |
CC148 Rabbit Polyclonal Antibody |
JOT-AP07176-100ul |
Jotbody |
100ul |
EUR 220 |
CC148 Rabbit Polyclonal Antibody |
JOT-AP07176-50ul |
Jotbody |
50ul |
EUR 144 |
CC149 Rabbit Polyclonal Antibody |
JOT-AP07181-100ul |
Jotbody |
100ul |
EUR 220 |
CC149 Rabbit Polyclonal Antibody |
JOT-AP07181-50ul |
Jotbody |
50ul |
EUR 144 |
CC150 Rabbit Polyclonal Antibody |
JOT-AP07196-100ul |
Jotbody |
100ul |
EUR 220 |
CC150 Rabbit Polyclonal Antibody |
JOT-AP07196-50ul |
Jotbody |
50ul |
EUR 144 |
CC152 Rabbit Polyclonal Antibody |
JOT-AP07197-100ul |
Jotbody |
100ul |
EUR 220 |
CC152 Rabbit Polyclonal Antibody |
JOT-AP07197-50ul |
Jotbody |
50ul |
EUR 144 |
CC153 Rabbit Polyclonal Antibody |
JOT-AP07241-100ul |
Jotbody |
100ul |
EUR 220 |
CC153 Rabbit Polyclonal Antibody |
JOT-AP07241-50ul |
Jotbody |
50ul |
EUR 144 |
CC154 Rabbit Polyclonal Antibody |
JOT-AP07242-100ul |
Jotbody |
100ul |
EUR 220 |
CC154 Rabbit Polyclonal Antibody |
JOT-AP07242-50ul |
Jotbody |
50ul |
EUR 144 |
CC155 Rabbit Polyclonal Antibody |
JOT-AP07251-100ul |
Jotbody |
100ul |
EUR 220 |
CC155 Rabbit Polyclonal Antibody |
JOT-AP07251-50ul |
Jotbody |
50ul |
EUR 144 |
CC157 Rabbit Polyclonal Antibody |
JOT-AP07252-100ul |
Jotbody |
100ul |
EUR 220 |
CC157 Rabbit Polyclonal Antibody |
JOT-AP07252-50ul |
Jotbody |
50ul |
EUR 144 |
CC032 Rabbit Polyclonal Antibody |
JOT-AP01152-100ul |
Jotbody |
100ul |
EUR 220 |
CC032 Rabbit Polyclonal Antibody |
JOT-AP01152-50ul |
Jotbody |
50ul |
EUR 144 |
CC036 Rabbit Polyclonal Antibody |
JOT-AP01153-100ul |
Jotbody |
100ul |
EUR 220 |
CC036 Rabbit Polyclonal Antibody |
JOT-AP01153-50ul |
Jotbody |
50ul |
EUR 144 |
CC037 Rabbit Polyclonal Antibody |
JOT-AP01154-100ul |
Jotbody |
100ul |
EUR 220 |
CC037 Rabbit Polyclonal Antibody |
JOT-AP01154-50ul |
Jotbody |
50ul |
EUR 144 |
CC043 Rabbit Polyclonal Antibody |
JOT-AP01155-100ul |
Jotbody |
100ul |
EUR 220 |
CC043 Rabbit Polyclonal Antibody |
JOT-AP01155-50ul |
Jotbody |
50ul |
EUR 144 |
CC056 Rabbit Polyclonal Antibody |
JOT-AP01156-100ul |
Jotbody |
100ul |
EUR 220 |
CC056 Rabbit Polyclonal Antibody |
JOT-AP01156-50ul |
Jotbody |
50ul |
EUR 144 |
CC062 Rabbit Polyclonal Antibody |
JOT-AP01157-100ul |
Jotbody |
100ul |
EUR 220 |
CC062 Rabbit Polyclonal Antibody |
JOT-AP01157-50ul |
Jotbody |
50ul |
EUR 144 |
CC070 Rabbit Polyclonal Antibody |
JOT-AP01158-100ul |
Jotbody |
100ul |
EUR 220 |
CC070 Rabbit Polyclonal Antibody |
JOT-AP01158-50ul |
Jotbody |
50ul |
EUR 144 |
CC071 Rabbit Polyclonal Antibody |
JOT-AP01159-100ul |
Jotbody |
100ul |
EUR 220 |
CC071 Rabbit Polyclonal Antibody |
JOT-AP01159-50ul |
Jotbody |
50ul |
EUR 144 |
CC080 Rabbit Polyclonal Antibody |
JOT-AP01172-100ul |
Jotbody |
100ul |
EUR 220 |
CC080 Rabbit Polyclonal Antibody |
JOT-AP01172-50ul |
Jotbody |
50ul |
EUR 144 |
CC124 Rabbit Polyclonal Antibody |
JOT-AP01175-100ul |
Jotbody |
100ul |
EUR 220 |
CC124 Rabbit Polyclonal Antibody |
JOT-AP01175-50ul |
Jotbody |
50ul |
EUR 144 |
CC146 Rabbit Polyclonal Antibody |
JOT-AP01190-100ul |
Jotbody |
100ul |
EUR 220 |
CC146 Rabbit Polyclonal Antibody |
JOT-AP01190-50ul |
Jotbody |
50ul |
EUR 144 |
CC159 Rabbit Polyclonal Antibody |
JOT-AP01210-100ul |
Jotbody |
100ul |
EUR 220 |
CC159 Rabbit Polyclonal Antibody |
JOT-AP01210-50ul |
Jotbody |
50ul |
EUR 144 |
CC170 Rabbit Polyclonal Antibody |
JOT-AP01211-100ul |
Jotbody |
100ul |
EUR 220 |
|
CC170 Rabbit Polyclonal Antibody |
JOT-AP01211-50ul |
Jotbody |
50ul |
EUR 144 |
|
CC017 Rabbit Polyclonal Antibody |
JOT-AP07050-100ul |
Jotbody |
100ul |
EUR 220 |
CC017 Rabbit Polyclonal Antibody |
JOT-AP07050-50ul |
Jotbody |
50ul |
EUR 144 |
CC019 Rabbit Polyclonal Antibody |
JOT-AP07053-100ul |
Jotbody |
100ul |
EUR 220 |
CC019 Rabbit Polyclonal Antibody |
JOT-AP07053-50ul |
Jotbody |
50ul |
EUR 144 |
CC020 Rabbit Polyclonal Antibody |
JOT-AP07086-100ul |
Jotbody |
100ul |
EUR 220 |
CC020 Rabbit Polyclonal Antibody |
JOT-AP07086-50ul |
Jotbody |
50ul |
EUR 144 |
CC024 Rabbit Polyclonal Antibody |
JOT-AP07099-100ul |
Jotbody |
100ul |
EUR 220 |
CC024 Rabbit Polyclonal Antibody |
JOT-AP07099-50ul |
Jotbody |
50ul |
EUR 144 |
CC072 Rabbit Polyclonal Antibody |
JOT-AP07115-100ul |
Jotbody |
100ul |
EUR 220 |
CC072 Rabbit Polyclonal Antibody |
JOT-AP07115-50ul |
Jotbody |
50ul |
EUR 144 |
CC058 Rabbit Polyclonal Antibody |
E10G30588 |
EnoGene |
100 μl |
EUR 275 |
Description: Biotin-Conjugated, FITC-Conjugated , AF350 Conjugated , AF405M-Conjugated ,AF488-Conjugated, AF514-Conjugated ,AF532-Conjugated, AF555-Conjugated ,AF568-Conjugated , HRP-Conjugated, AF405S-Conjugated, AF405L-Conjugated , AF546-Conjugated, AF594-Conjugated , AF610-Conjugated, AF635-Conjugated , AF647-Conjugated , AF680-Conjugated , AF700-Conjugated , AF750-Conjugated , AF790-Conjugated , APC-Conjugated , PE-Conjugated , Cy3-Conjugated , Cy5-Conjugated , Cy5.5-Conjugated , Cy7-Conjugated Antibody |
CC50A Rabbit Polyclonal Antibody